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Nonobese Patients With Familial Combined 
Hyperlipidemia Are Insulin Resistant Compared 
With Their Nonaffected Relatives
Sebastian J.H. Bredie, Cees JJ . Tack, Paul Smits, Anton F.H. Stalenhoef
Abstract Familial combined hyperlipidemia (FCH) is a het­
erogeneous lipid disorder, caused by overproduction of VLDL 
and characterized by the occurrence of small, dense LDL parti­
cles, all features that are also associated with insulin resistance. 
Therefore, insulin sensitivity was examined directly by means 
of the euglycemic hyperinsulmemic clamp technique in male 
nonobese, normotensive FCH patients and compared with that 
of their nonaffected relatives, matched for age and body mass 
index (BMI). In addition, an oral 75-g glucose tolerance test 
(OGTT) was performed and lipid values, including the LDL 
subfraction profile, were determined. During the clamp, forearm 
blood flow (FBF) was measured by venous occlusion plethys­
mography. All participants had a normal glucose response after 
the glucose load, whereas FCH patients showed hyperinsulin- 
emia after OGTT and higher fasting C-peptide levels. During 
the clamp, insulin concentrations increased equally in both 
groups. Mean whole-body glucose uptake (M) (120 to 180 min­
utes) was lower in FCH patients than in nonaffected relatives 
(6.89±0.31 versus 8.94±0.76 mg • kg"1 • min”1; .P=.()l). In addi­
tion, the glucose uptake per unit insulin (I) was lower in FCH 
patients (insulin sensitivity index [M/I], 7.46±0.50 versus
9.51 ±0.53; P=.009). M significantly correlated with BMI,
'i
plasma cholesterol and triglyceride concentrations, and the indi­
vidual LDL density. The FBF correlated with insulin sensitivity 
and increased significantly in nonaffected relatives (1.9±0.12 to 
2.5±0.4 mL • min“1 • dL-1; J°=.025) but not in patients. Thus, 
FCH patients characterized by a predominance of small, dense 
LDL are insulin resistant compared with their nonaffected rela­
tives. This insulin resistance may partly be explained by a 
decreased insulin-induced vasodilation in skeletal muscle. 
(Arterioscler Thromb Vase Biol. 1997;17:1465-1471.)
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amilial combined hyperlipidemia is a common 
heritable  and he terogeneous lipid d isorder 
characterized by the presence of a multiple-type 
hyperlipidemia with elevated plasma cholesterol and/or 
plasma triglyceride levels and the frequent occurrence of 
premature cardiovascular disease in first-degree rela­
tives.1-3 Originally, FCH was supposed to be caused by 
the variable expression of a single autosomal dominant 
gene primarily regulating plasma triglyceride levels and 
secondarily affecting cholesterol levels.1 However, sev­
eral metabolic and b iochem ical defects  that have 
recently been related to the trait suggest that the genetic 
basis of FCH is more heterogeneous. As a consequence, 
the spectrum of FCH also comprises other related pheno­
types, such as hyperapobetalipoproteinemia,4 the LDL 
subclass pattern B phenotype,5 familial dyslipidémie 
hypertension,6 and some features of the insulin resis­
tance syndrome.7'0
Insulin resistance, defined as a decreased ability of 
insulin to stimulate glucose uptake, is increasingly rec­
ognized as a common factor underlying various condi­
tions, all of which predispose to coronary heart dis­
ease.10 Resistance to normal action of insulin is related 
to alterations in lipid metabolism such as an excessive
postprandial release of NEFAs due to impaired suppres­
sion of hormone-sensitive lipase activity.11 An increased 
supply of fatty acids to liver cells is associated with 
VLDL overproduction,12,13 whereas an impaired activa­
tion of lipoprotein lipase adds to reduced clearance of 
triglyceride-rich lipoproteins.14 In addition, insulin resis­
tance may coincide with a predominance of small, dense 
LDL particles, as demonstrated in some studies,6,I5,K1 
although this observation has been countered by others.17 
Since these features (ie, VLDL overproduction, impaired 
lipoprotein lipase activity, and a predominance of small, 
dense LDL) are also characteristics of FCH, the exis­
tence of insulin resistance may be an important factor 
modulating FCH phenotypes. The interpretation of data
between insulin sensitivityconcerning
and lipid disturbances is, however, hampered by the fact 
that several features related to lipid disorders, such as 
visceral obesity, age, sex, hypertension, and existence of 
cardiovascular disease, are 
with insulin resistance. Furthermore, hyperinsulinemia, 
as a consequence of insulin resistance, has been directly 
associated with cardiovascular disease.18
assocu
Recent reports hypothesized that diminished 
uptake may partly be explained by a decreased insu I in-
in skeletal muscle. |l>,2(t Fuiinduced vat
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more, insulin’s effect on vascular tone has
to be nitric oxide dependent.21 Interestingly 
demic patients, endothelium-dependent vas 
been shown to be diminished.22,23
Several earlier reports have suggested the presence of 
insulin resistance in various forms of hyperlipidemia. 
However, these findings were either based on rather 
indirect measurements such as determination of plasma
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Selected Abbreviations and Acronyms
BMI = body mass index
FBF = forearm blood flow
FCH = familial combined hyperlipidemia
Hb =
I =
hemoglobin
insulin
M = mean whole-body glucose uptake 
MAP = mean arterial pressure 
NEFA = nonesterified fatty acid 
OGTT = oral glucose tolerance test
concentrations of glucose, insulin, and NEFA,8 possibly 
confounded by obesity of the study group,9 or obtained 
by steady state plasma glucose and insulin concentration 
determinations after som atosta tin  adm in is tra tion .7 
Somatostatin in itself may exhibit vascular effects. 
Therefore, in this study we have determined the sensitiv­
ity to the metabolic and hemodynamic effects of insulin 
directly by means of the euglycemic hyperinsulinemic 
clamp technique in combination with skeletal blood flow 
measurements. The studies were performed in a care­
fully selected sample of well-defined nonobese nor- 
motensive male FCH patients, which were compared 
with matched nonaffected relatives.
Methods
Subj ects
For this study, initially 12 unrelated nonobese normotensive 
male FCH patients, selected from an available sample of well- 
defined Dutch FCH families, were compared with one of their 
nonaffected male relatives. To anticipate environmental influ­
ences, we carefully matched related individuals (ie, affected and 
unaffected) for age, BMI, and waist-to-hip ratio. In addition, all 
subjects were apparently healthy and met the following inclu­
sion criteria: BMI <27 kg/m2; blood pressure <165/90 mm Hg 
(measured in the supine position after 5 minutes’ rest); absence 
of diabetes mellitus, a medical history of vascular disease, and 
use of any medication except lipid-lowering drugs, which were 
discontinued at least 1 month before participation. Two FCH 
patients and two relatives were habitual smokers.
The FCH diagnosis was based on the following criteria: (1) 
the presence of a multiple-type hyperlipidemia in first-degree 
relatives, with at least two first-degree relatives with a different 
hyperlipidemia (ie, hypertriglyceridemia, hypercholesterolemia, 
or a combined hyperlipidemia). The assessment of hyperlipi­
demia was based on the presence of constant elevated choles­
terol and/or triglyceride levels above the 90th percentile, in 
spite of dietary advice24; (2) a positive family history of prema­
ture cardiovascular disease before the age of 60 years.
Participating FCH patients had both total plasma cholesterol 
and triglyceride concentrations above the 90th percentile for age 
and sex after dietary advice and after withdrawal of lipid- 
lowering drugs for at least 4 weeks. In contrast, unaffected rela­
tives (nine were brothers; two were cousins) had both total 
plasma cholesterol and triglyceride concentrations below the 
75th percentile for age and sex. None of the subjects was 
homozygous for the apoE2 allele.
Protocol and Procedures
All participants were asked to visit the department twice after 
an overnight fast. During a first visit, a questionnaire was filled 
out to collect information on medical status, and supine blood 
pressure, BMI, and waist-to-hip ratio were measured. Further­
more, blood was sampled for determination of baseline values 
for lipids, lipoproteins, HbAic. and C-peptide and for determi­
nation of the individual distribution of LDL subfractions in the 
LDL subfraction profile. Moreover, a 75-g OGTT was per­
formed to exclude impaired glucose tolerance or overt diabetes 
mellitus. In these tests, glucose and insulin concentrations were 
determined at baseline and 30, 60, 90, and 120 minutes after the 
glucose load. Only when participants showed 2-hour postload 
glucose levels <7.8 mmol/L was a hyperinsulinemic euglycemic 
clamp performed, combined with hemodynamic measurement of 
blood pressure, heart rate, and FBF, during a second visit, I to 2 
weeks later. After OGTT, one FCH patient and his related con­
trol subject were excluded from further analyses due to impaired 
glucose tolerance of this FCH patient (2-hour glucose level of 
10.2 mmol/L). The experimental protocol was approved by the 
ethical committee of our hospital, and all participants gave their 
written informed consent.
Euglycemic Hyperinsulinemic Clamp
Experiments were performed with the participants in the 
supine position in a quiet, temperature-controlled room (24”C to 
25°C). Under local anesthesia (0.3 to 0.4 mL lidoeaine HC1, 20 
ing/mL), a 20-gauge catheter (Angiocath, Deseret Medical Inc, 
Becton Dickinson) was inserted into the left brachial artery and 
connected with an arterial pressure monitoring line (Viggo 
Spectramed, No. 992399A/14368) to a Hewlett Packard monitor 
(type 78353B, Hewlett Packard GmbH). MAP was determined 
by an electronically integrated area under the brachial arterial 
pulsed-wave form. The arterial line was kept patent with saline 
infusion (with 2 U heparin per milliliter added). On the con­
tralateral side, an identical venous catheter was inserted into a 
large forearm vein for infusion of insulin and glucose. Insulin 
(Actrapid, Novo-Nordisk) was infused in a dose of 60 mU/m2 
per minute for 180 minutes. Insulin was diluted in 50 mL 0.9% 
NaCl with addition of 2 mL albumin, to a concentration of 1 
U/mL. According to the clamp technique,25 plasma glucose con­
centration was kept at a euglycemic level by a variable infusion 
of glucose 20% solution, adjusted by arterial plasma glucose 
levels measured at 5-minute intervals. All subjects were 
clamped at fasting glucose levels minus 0.3 mmol/L. The glu­
cose infusion rate was calculated as the given amount of glucose 
in milliliters per kilogram body weight per minute, which equals 
M. The glucose uptake per plasma unit of insulin (1) (insulin 
sensitivity index, calculated as M/1) was determined as an addi­
tional measure of insulin sensitivity. In addition, the concentra­
tions of NEFAs were determined before and at the end.
FBF Measurement
FBF was measured using a mercury-in-siliconc elastomer 
strain-gauge venous occlusion plethysmography on both arms as 
previously described.2f’ One minute before the start of the mea­
surements (which were taken every 30 minutes), a wrist cuff 
was inflated to 100 mm Hg above the systolic blood pressure, to 
be sure that the measurement referred only to the forearm skele­
tal muscle vascular bed.27 The collecting cuff around the upper 
arm was inflated to a pressure of 45 mm Hg during 8 to 10 heart 
cycles by using a rapid cuff inflator (Hokanson E20 rapid cuff 
inflator, Hokanson Inc). The strain gauges were connected to a 
plethysmograph (Hokanson EC4 plethysmograph, Hokanson 
Inc). Changes in FBF during the clamp procedure were calcu­
lated with the means of the left and right FBF.
Analytical Methods
Glucose concentrations were measured in duplicate by using 
the oxidation method (Beckman Glucose Analyser2, Beckman 
Instruments Inc). Plasma insulin concentrations were deter- 
mined using an “in-house” assay (double antibody method) with 
an interassay variability of 6%. C-peptide was determined using 
a commercial double antibody kit (Diagnostic Products Corp, 
catalog No. KPED1 double antibody), with an interassay vari­
ability of 4.3%. HbAic was determined with a high-perfor­
mance liquid chromatography technique (Biorad Laboratories), 
with a reference range of 4.8% to 6.2%. The concentrations of 
NEFAs were determined using a commercially available ACS- 
ACOD method (Waco Chemicals GmbH, catalog No. 994-
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T a b le  1. Baseline Anthropomorphic Measurements; 
BP; and Lipid, Lipoprotein, and ApoB Levels in FCH 
Patients and Their Unaffected Relatives
T a b le  2. Baseline Concentrations of Parameters of 
Glucose Metabolism in 11 FCH Patients and 11 
Unaffected Relatives
Affected Unaffected P
n 11 11 NS
Age, y 41,9±9.0 44.9±11.5 NS
BMI, kg/m2 24.9±1.2 24.3±1.5 NS
Waist-to-hip ratio 0.99/0.05 1.00/0.04 NS
Systolic BP, mm Hg 122.7±11.7 132.7±16.5 NS
Diastolic BP, mm Hg 79.5±6.9 81,8±8.4 NS
Total chol* 7.70±1.01 5.59±0.85 .003
Total TG* 3.73±2.50 1,24±0.43 .003
VLDL chol* 1.90±1.40 0.50±0.29 .003
VLDL TG*
> 2.80±2.14 0.71 ±0.41 .003
LDL chol* 4.90±1.39 4.03±0.S8 NS
HDL chol* 0.89±0.17 1.20±0.15 .006
ApoB, mg/dL 178.9±45.3 122.8±26.8 .003
K value -0.62±0.13 —0.08±0.24 .004
BP indicates blood pressure; chol, cholesterol; TG, triglyceride; and 
NS, not significant. All values except n and walst-to-hip ratio are 
mean±SD.
‘Values in mmol/L.
75409). Total plasma cholesterol and triglyceride concentra­
tions were determined by commercially available enzymatic 
reagents (Boerhinger-Mannheim, catalog No. 237574 and Sera 
Pak, catalog No. 6639, respectively). VLDL was isolated from 
whole plasma by sequential ultracentrifugation at <¿=1.019 g/mL 
for 16 hours at 36 000 rpm in a fixed-angle rotor (TFT 45.6 
rotor, Kontron) in a Beckman L7-55 ultracentrifuge (Beckman). 
HDL cholesterol was determined with the polyethylene glycol 
6000 method.28 LDL cholesterol was calculated by subtraction 
of VLDL and HDL cholesterol from total plasma cholesterol. 
Total plasma apolipoprotein B was determined by immunoneph- 
elometry.29 To achieve accurate results in relation to the Centers 
for Disease Control Lipid S tandard iza tion  Program , the 
obtained plasma apoB results were recalculated on the basis of 
exchange of sera with Dr S. Marcovina (Northwest Lipid 
Research Laboratory, Seattle, Wash). LDL subfractions were 
detected by single-spin density-gradient ultracentrifugation, 
according to a method described elsewhere.30'31 After ultracen­
trifugation , up to five LDL su b frac tio n s ,  s ta ined  w ith 
Coomassie brilliant blue R, were visible as distinct bands in the 
middle of the tube. Accurate documentation of the different 
LDL subfraction patterns was obtained by scanning slides of the 
tubes in triplicate on an LKB 2202 ultrascan laser densitometer 
(Pharmacia LKB). The mean peak heights (hi to h5) of the LDL 
subfractions (LDL1 to LDL5) on the three scans were used to 
calculate a continuous variable K (— 1 <K< 1), as described else-
This continuous variable K appeared to reflect appro­
priately the individual LDL subfraction profiles.32,33 A negative 
K value (-l<K <0) reflects an LDL subfraction profile more or 
less predominated by small, dense subfractions. A profile with a 
predominance of buoyant LDL subfractions reveals a positive K 
value (0£K<1).
Statistical Analysis
Differences in baseline characteristics and baseline values for 
lipid, lipoproteins, glucose, and IibA ic were tested by the non- 
parametric two-sample Wilcoxon signed rank test. The results 
of the glucose tolerance test were tested by comparing areas 
under the curve of both the glucose excursion curve and the 
insulin response. To compare M and the insulin sensitivity index 
of the affected with that of the unaffected subjects, controlling 
for possible influence of confounding variables, an ANOVA 
was performed, with age, BMI, and waist-to-hip ratio as covari- 
ates. To investigate differences in the time of action of insulin 
on hemodynamic parameters between the two groups, the 
time/group interaction was calculated by repeated-measures 
ANOVA, with insulin as the dependent factor. All statistical
Affected Unaffected P
Glucose, mmol/L 5.45±0.12 5.22±0.15 NS
Insulin, mU/L 8.55±0.95 7.00±0.98 NS
HbAic, % 5.45±0.10 5.36±0.08 NS
C peptide, nmol/L 0.65±0.03 0.47±0.04 .02
lnsulin-to-glucose ratio 1.57±0.18 1.35±0.18 NS
NEFA 0.86±0,16 0.75±0.05 NS
NS indicates not significant. All values except those for l-to-glucose 
ratio are mean±SEM.
analysis were performed using the SPSS/PC+ program (SPSS 
Inc). Results in tables and figures are presented as mean±SEM 
unless otherwise indicated. Differences with a test value <.05 
were considered to be significant.
Results
Baseline Characteristics
Baseline characteristics of both 11 FCH patients and 
their 11 nonaffected relatives are presented in Table 1. 
Age, BMI, waist-to-hip ratio, and blood pressure were 
not different between the groups. As a consequence of 
the selection procedure, all lipid and lipoprotein concen­
trations (except the LDL cholesterol concentration) were
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Fig 1. Results of th© 75-g OGTT in 11 FCH patients and 11 
unaffected relatives. Upper panel, mean glucose curves of FCH
patients (■ )  and unaffected control subjects (□ ). Calculated 
areas under the curve were not significantly different, but mean 
glucose concentration at 120 minutes was significantly higher in 
patients than in control subjects. Lower panel, mean insulin
response curves of FCH patients (■ ) and unaffected control 
subjects (□ ). Calculated areas under the curve were signifi­
cantly higher in FCH.
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significantly higher in FCH patients than in the unaf­
fected relatives. Total plasma apoB was also higher in 
FCH patients than in unaffected relatives. The K value, 
as a description of the LDL subfraction profile, was 
more negative in FCH patients than in unaffected rela­
tives, corresponding with the predominance of small, 
dense LDL particles in FCH patients.
Responses to Oral 75-g Glucose Load
Baseline values of fasting glucose, fasting insulin, 
HbAic, C-peptide, and the calculated insulin-to-glucose 
ratio are presented in Table 2. C-peptide concentrations 
were significantly higher in FCH patients than in their 
unaffected relatives. Concentrations of glucose, insulin, 
HbAic, and insulin-to-glucose ratio all tended to be 
higher in FCH patients than in the unaffected relatives, 
but these differences did not reach significant levels. 
Glucose concentrations after oral glucose load were 
comparable in both groups (Fig 1), although a signifi­
cantly higher glucose concentration after 2 hours was 
observed in FCH patients compared with the control sub­
jects (5.73±0.52 mmol/L versus 4.36±0.29 mmol/L, 
P=.019). Plasma insulin responses during the 2 hours 
after the oral glucose load, also presented in Fig 1, were 
significantly higher in patients than control subjects. All 
included participants had a normal glucose tolerance by 
exhibiting plasma glucose levels <7.8 mmol/L 2 hours 
after an oral 75-g glucose load.
Metabolic Response to Clamp Procedure
Plasma glucose values during the last 60 minutes of 
the clamp procedure were stable in patients and unaf­
fected relatives (coefficient of variation, 3.4±0.3% and 
4.1±0.3%, respectively). Plasma insulin concentrations 
increased in all subjects and were similar after 3 hours of
relatives was very similar to previously obtained values 
of healthy volunteers (8.8± 1.3 mg ■ kg' 1 • min 1).34 The
glucose uptake during the last 60 minutes of the clamp 
procedure per plasma unit of insulin (insulin sensitivity 
index) also differed between the groups (M/I, 7.46±0.50 
versus 9.51±0.53, respectively; P=.009 by ANOVA). 
When the results of the related couples were compared, 
it was found that in nine FCH patients M was lower, in 
one FCH patient it was equal, and in one FCH patient it 
was higher than in their respective normolipidemic rela­
tives (Fig 3). To avoid the possible confounding effect of 
smoking, the rates of uptake were also compared in non- 
smokers. In nonsmokers, the rates of M were also signif­
icantly lower in FCH patients (n=9) than in unaffected 
relatives (n=9) (6.90±0.66 versus 9.00±0.93 mg • kg"1 • 
min“1, respectively; P=.019 by ANOVA). Although fast­
ing plasma NEFA concentrations were higher in the FCH 
patients than in control subjects, this difference appeared 
not to be significant (Table 2). Both NEFA concentra­
tions were suppressed in a similar manner during the 
clamp procedure (from 0.86±0.16 to 0.12±0.04 mmol/L 
in FCH patients, P= .003, and from 0.75±0.12 to 
0.10±0.05 mmol/L in unaffected relatives, P=.003), 
without differences between the groups.
Effects on FBF
At baseline, the mean values of hemodynamic param­
eters (FBF and MAP) of both groups were similar. Only 
unaffected relatives exhibited a significant increase of
31.8±14.3% in FBF (FBF from 1.85±0.16 to 2.45±0.35 
mL • m in"1 • dL"1, ANOVA P=.025), whereas FCH 
pa tien ts  show ed  no s ig n i f ic a n t  ch an g e  in FBF 
(1.87±0.15 to 2.06±0.24). MAP did not change in either 
group (FCH patients: 92.7±2.3 to 93.0±3.6 and relatives: 
95.3±3.0 to 98.4±2.7 mm Hg). The time course of the
insulin infusion in both groups (94.6±4.3 mU/L in FCH changes in FBF showed the major and statistically sig- 
patients and 93.8±4.8 mU/L in unaffected relatives). M, nificant changes during the last hour of the clamp,
calculated from the glucose infusion rate of both groups 
during the clamp procedure, is presented in Fig 2 and 
was significantly different over the last 60 minutes 
be tw een  FCH p a t ien ts  and u n a ffec ted  re la t iv es
(6.89±0.31 versus 8.94±0.76 mg • kg mm i respec
tively; P=.01 by ANOVA). The M value of the control
reflecting a phenomenon with .slow onset.
Relationship Between LDL Subfraction 
Distribution and M
The individual LDL subfraction profile, described as 
parameter K, correlated significantly with the glucose
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Fig 2. Results of the euglycemic hyperinsu- 
linemic clamp procedure during 3 hours in 11 
FCH patients and 11 unaffected relatives. Left, 
y  axis, mean glucose concentrations of FCH 
patients (■ )  and unaffected control subjects 
(□ ) are presented in the upper lines. Right y 
axis, significantly different mean glucose infu­
sion rates (milligrams per kilogram per minute) 
as a measure of glucose uptake during the 
clamp procedure of affected (solid bars) and 
unaffected (open bars) subjects are shown.
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Fig 3. Comparison of M during clamp procedure of related 
couples (ie, FCH patients and relatives) connected by lines. 
One FCH patient had equal glucose uptake and one had lower 
glucose uptake during the clamp procedure than his relative.
uptake during the clamp procedure (Pearson’s r=.51, 
P=.008; Fig 4). When the groups were compared sepa­
rately, FCH patients were more insulin resistant and 
exhibited a predominance of small, dense LDL subfrac­
tions. The unaffected relatives, with the exception of one 
individual, were characterized by the presence of more 
buoyant LDL particles.
Discussion
In this study, we demonstrated directly by means of 
the euglycemic clamp technique a reduced insulin sensi­
tivity in well-defined male FCH patients compared with 
one of their normolipidemic relatives. Since it has been 
established that insulin resistance is also associated with 
obesity, age, and sex alone,35,36 it is important to empha­
size that these observations were not confounded by dif­
ferences in sex or age and were registered in the absence 
of obesity, hypertension, and impaired glucose tolerance 
in the participants. Furtherm ore, we
a f f e c t e d
the
unaffected participants in genetically
related pairs, presuming that by this study design, dif­
ferences in environmental or genetic influences were 
reduced. Apart from the metabolic resistance to insulin 
(reduced glucose uptake), FCH patients also exhibited 
resistance to the vasodilator effects of insulin. Finally, 
diminished M correlated with the presence of small, 
dense LDL subfractions.
Because of the similarity in presenting lipid distur­
bances and the association with increased cardiovascular 
risk, diminished insulin sensitivity may be related to 
FCH. This observation is further supported by the find­
ing that insulin resistance affects both hepatic VLDL 
production and lipoprotein lipase action features also 
met in FCH. Previous studies indicate that insulin resis­
tance is associated with elevated concentrations of 
VLDL tr ig lyceride .7,37,38 Recent studies, however, 
showed no improvement in insulin sensitivity after sub­
stantial reduction of plasma triglyceride levels with 
fibrate treatment in both nondiabetic men with type lib 
hyperlipidemia and in type II diabetic patients with 
hypertriglyceridemia.39,40 This factor may indicate that 
in some patients insulin resistance is of an inherited 
nature, not dependent on plasma triglyceride concentra­
tions but probably preceding VLDL triglyceride over­
production.
A proposed mechanism responsible for VLDL over­
production is the impaired postprandial suppression of 
NEFA release in adipose tissue due to resistance to the 
normal suppressive effect of insulin on hormone- 
sensitive lipase.11,41 An elevated concentration of NEFA 
is associated with increased hepatic VLDL triglyceride
due to reduced intracellular apoBsecretion,
d e g ra d a t io n .12 Furtherm ore, when normal insulin- 
mediated activation of lipoprotein lipase in adipose tis­
sue is diminished, an impaired postprandial clearance of 
tr ig lyceride-rich  lipoproteins may o ccu r .14 Several 
reports mentioned an impaired lipoprotein lipase activity 
as one of the factors contributing to FCH.42,43
A postprandial status with prolonged circulating
ìins is a provoking situation for
14 In thethe formation of small, dense LDL 
Kaiser Permanente Women Twin study and other stud­
ies, small, dense LDL was found to be an integral feature 
of the insulin resistance syndrome.|S,I<’ Others
Fig 4. Correlation between glucose uptake during 
the clamp procedure and LDL density as deter­
mined by density-gradlent ultracentrifugation and
described by parameter K. FCH patients (■ ) and 
unaffected relatives(C l) are depicted (r=.51, 
P=.008).
LDL density (K-value)
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showed a significant correlation between LDL particle 
size and triglyceride levels but not insulin resistance in 
mildly hypertriglyceridemic subjects.17 Here, the authors 
considered small, dense LDL a feature of the insulin 
resistance syndrome more as a consequence of abnor­
malities in VLDL metabolism. Our observed correlation 
between glucose uptake as a measure of insulin sensitiv­
ity and LDL density is in accordance with these reports 
but cannot discriminate between metabolic influences, 
such as the correlation with hypertriglyceridemia, caus­
ing a dense LDL subfraction profile, or primarily genetic 
effects related to diminished insulin sensitivity and 
small, dense LDL in FCH. The recently reported major 
gene effect on LDL subfraction size in FCH5’33 may pos­
sibly be found in mutations causing insulin resistance 
underlying hypertriglyceridemia and the formation of 
small, dense LDL. On the other hand, reported linkage of 
small, dense LDL to a locus near the LDL receptor and 
the insulin receptor gene on chromosome 19p45 may 
indicate that the allele responsible for expression of 
small, dense LDL also predisposes to insulin resistance.
Disorders related to insulin resistance seem to exhibit 
their major defect on the level of glucose uptake in 
skeletal muscle rather than at the level of the liver or the 
adipose tissue.46'48 Furthermore, several groups, includ­
ing ourselves, have demonstrated the vasodilator effect 
of systemic hyperinsulinemia,19,34,49 which was reduced 
in non-insu lin-dependent diabetes m ellitus .50 It is 
hypothesized that decreased  insulin  sensitivity in 
humans may be due not only to lower insulin-mediated 
glucose extraction in insulin-sensitive tissues but also to 
a lower blood flow to these tissues, due to a decreased 
ability of insulin to stimulate skeletal muscle blood 
flow.20 In accordance with other studies in which compa­
rable systemic insulin concentrations were reached, we 
observed a 30% increase in FBF in nonaffected subjects 
but not FCH patients. Although part of the present 
reported insulin resistance may be related to this dimin­
ished insulin-induced vasodilation, this factor could in 
fact only account for the last 60 to 80 minutes of the 
clamp, since differences in FBF between the groups 
became statistically significant in this period.
The insulin-induced vasodilation seems to be endothe­
lium dependent.21 Reduced insulin-induced vasodilation 
may be due to direct endothelium-disturbing action of 
elevated lipid levels.23 Therefore, in FCH patients, the 
elevated lipoprotein concentration may directly influ­
ence the endothelium function, resulting in decreased 
nitric oxide release during hyperinsulinemia. Because 
insulin resistance itself may underlie VLDL overproduc­
tion, the reduced hemodynamic effects of insulin in
hyperlipidemia can amplify metabolic disturbances 
found in FCH patients.
Recently, the Insulin Resistance Atherosclerosis 
Study demonstrated an inverse association between 
insulin sensitivity and atherosclerosis, as assessed by 
B-mode ultrasonography of the carotid artery wall. 51 
This association was eliminated, although not com­
pletely, by correction for traditional cardiovascular risk 
factors. Insulin resistance in our FCH patients, who 
were exposed to elevated lipid levels for a relatively 
short period of time (mean age <42 years) and without 
signs of a therosclerosis , represents more likely a 
metabolic defect rather than the consequence of exist­
ing atherosclerosis.
In conclusion, this study suggests that FCH patients 
exhibit a diminished insulin sensitivity. This insulin 
resistance may underlie the observed hyperlipidemia, 
characterized by elevated concentrations of VLDL 
cholesterol and triglycerides and a predominance of 
small, dense LDL in the affected subjects, and may be 
partly explained by a reduced capacity of insulin to 
induce vasodilation in skeletal muscle of the patients. 
Therefore, interactions between insulin action and lipid 
metabolism in FCH warrant further investigation.
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